Patient Assistance
DiviTum^® TKa
Who We Help
Who We Are
Investor Relations

Investor Relations

Investor Relations

Press Releases

The Share

Stock Quote & Chart
Analyst Coverage
Shareholders
Insider
Conversion of A-shares

Financial Reports

Rights Issue 2025

Rights Issue 2023

Rights Issue 2022

Prospectus 2017

Calendar

Investor Events

Certified Adviser

Subscribe

IR Contact

Corporate Governance

Articles of Association
Board of Directors
Management Team
Nomination Committee
AGM and EGM
Remuneration

Insider positions

Buy & sell transactions

>4,500

Numbers of patients in studies

28

Publications

32

Pharma Projects

DiviTum^® TKa is CE marked in Europe and FDA 510(k) cleared in the United States.

The DiviTum^® TKa method and kit are protected under
US Patent Nos. 8,765,378 and 9,376,707.
Patent protection in 49 countries
DiviTum^® is a registered trademark of Biovica International AB

Sitemap

DiviTum®TKa
Who we help
Who we are
Investor Relations
Contact
Privacy Policy
Terms and Conditions

Investor Relations

The Share
Financial Reports
Calendar
Events
Certified adviser
Subscribe
IR Contact
Press releases
Corporate Governance

Sweden

info@biovica.com
+46 (0) 18 44 44 830

Dag Hammarskjölds väg 54B
Uppsala Science Park 752 37 Uppsala

USA

Main: +1 (858) 230-6044
Fax: +1 (858) 230-6174

6195 Cornerstone Court E
Suite 101
San Diego, CA 92121

Follow us

facebook
linkedin
x
youtube

© 2023 Biovica International AB. All Rights Reserved.
About cookies

Search the site

Search on Biovica

Your search

Required

Are you a US resident?

Only US residents will be able to qualify for this program

No